explore -WSS

explore

author：entertainment 2025-10-01 23:00:54 - browse：5

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Physician executives need more than on

Wikipedia

hotspot

WSS

Sana to lay off nearly a third of staff, de

Bristol 'take

FDA endorses new sterilization method for medical devices

Printout prescription drug information shouldn’t go digital

Dana Farber says 6 studies to be retracted and 31 corrected

Dana Farber says 6 studies to be retracted and 31 corrected

hotspot

explore

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Liquid biopsy for lung cancer is launched by Delfi

After affirmative action ruling, medical educators look to 'holistic review'

Mass General, Mayo Clinic look to monetize custom

How to save PrEP access — and even expand it

What causes osteoarthritis? Researchers study link to brain protein

Hepatitis C has a cure — but many Americans still lack access to it

CVS is on a mission to consolidate health care. Will it work?

Apple is now the first public company to be valued at $3 trillion

FDA authorizes Novavax’s updated Covid

Wikipedia

Colorectal cancer study finds potential in overlooked immune cell

FDA authorizes Novavax’s updated Covid

FDA rejects Alnylam's heart disease treatment over insufficient data

There's an unseen cost to disruptive road

Inaction leaves children at risk from dangerous chemotherapy drug

Prior authorization reform is both possible and imperative

Wikipedia

entertainment

hotspot

focus